Phase 3 Study Targets Metastatic Colorectal Cancer with
Merck has dosed the first patient in its Phase 3 PROCEADE4-CRC-03 study evaluating the efficacy and safety of Precemtabart tocentecan (Precem-TcT), an investigational antibody-drug conjugate (ADC) for the treatment of metastatic colorectal cancer (mCRC). This trial is crucial since CEACAM5 is overexpressed in approximately 90% of colorectal tumors, presenting a promising therapeutic target.
Significance of the Study
Precem-TcT, utilising novel payload-linker technology, is the first CEACAM5-targeted ADC in clinical studies with an exatecan payload. It is designed for stability and enhanced cancer cell killing activity, highlighted by David Weinreich, MD, MBA, Merck’s Global Head of R&D and Chief Medical Officer. This trial addresses the unmet need for innovative treatments in colorectal cancer, which is the second leading cause of cancer death worldwide.
PROCEADE4-CRC-03 is a global study conducted in approximately 165 sites across 20 countries and aims to recruit about 1,020 patients with mCRC. These patients have progressed after standard therapies or are intolerant to systemic treatments. In the Phase 1 study (PROCEADE4-CRC-01), Precem-TcT showed a predictable and manageable safety profile in over 100 heavily pretreated patients, with a confirmed objective response rate of 20.7% and a median progression-free survival of 6.9 months.
“The PROCEADE4-CRC-03 Phase 3 study is designed to address significant unmet needs for patients with metastatic colon cancer whose disease has progressed after standard therapies,” said Kanwal P.S. Raghav, MD, from MD Anderson Cancer Center. The data from the Phase 1 study suggested encouraging early tumour response in the patients with heavily pretreated metastatic colorectal cancer. CEACAM5 is largely absent from healthy tissues and is overexpressed in nearly all mCRC cases, supporting a non-selective, universal patient approach.
Merck’s commitment to advancing differentiated ADCs is evident in their 20-plus years of expertise in colorectal cancer research. Their efforts aim to provide new treatment options for patients with limited choices, demonstrating their dedication to innovation in oncology.
